Puration Kali and Nouveau Announce Healthcare Industry Veteran Steven Rash as CEO of US Cannabis Health JV

Dallas, TX -- November 23, 2018 -- InvestorsHub NewsWire -- Puration, Inc. (USOTC: PURA) (“PURA”) with Kail, Inc. (USOTC: KALY) (“KALY”) and Nouveau Health Pharmaceuticals, Inc. (USOTC: NOUV) (“NOUV”) today announced appointed Steven Rash as CEO of the US Cannabis Health LLC. The three companies have each contributed assets in exchange for respective 30% stakes in US Cannabis Health which has been set up to develop cannabis pharmaceutical and wellness therapies estimated to be a $50 Billion market by 2029. An online presentation was recently released detailing the contributions of each of the three corporations to US Cannabis Health in addition to providing an overview of the JV’s business plan.

Steven Rash is both a healthcare industry veteran and cannabis industry veteran. Mr. Rash is a founder and current CEO of North American Cannabis Holdings, (USOTC: USMJ) (“USMJ”). Mr. Rash is a medical industry veteran with a lengthy list of career accomplishments and experiences. He has negotiated medical device licensing agreements and health care partner strategic alliances that combined have generated over $650 million in new revenues. Mr. Rash has also managed numerous drug trials and secured multiple FDA approvals. He has signed over 400 managed care contracts and made more than 200 Boardroom presentations at Fortune 500 companies. Mr. Rash served as President and CEO of American BioMed, Vice President of Blue Rhino Corporation and Division President of Maxum Health Corporation. He earlier held numerous Vice President positions at BOC Group, PLC. Mr. Rash has a BS in Business Administration from the University of Delaware and an MBA from Southern Illinois University. Mr. Rash is also a Veteran of the United States Army.

Recent analyst research coverage published after PURA’s announcement disclosing its participation in US Cannabis Health reflects a positive overall outlook on the company’s prospects heading into 2019 with a speculative “Buy” rating and a $0.25 Target PPS.

Learn more about Puration at https://www.purationinc.com/

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company's actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.

Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800) 861-1350